We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in 4D Molecular Therapeutics, Inc. (FDMT): Can Its 16.0% Jump Turn into More Strength?
Read MoreHide Full Article
4D Molecular Therapeutics, Inc. (FDMT - Free Report) shares rallied 16% in the last trading session to close at $8.93. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.2% loss over the past four weeks.
The stock's surge can be attributed to the investors’ optimism around the company's third-quarter earnings, to be released soon. The optimism is being driven by the drug/biotech sector’s growth in the ongoing year.
This company is expected to post quarterly loss of $0.85 per share in its upcoming report, which represents a year-over-year change of -3.7%. Revenues are expected to be $1.7 million, up 24.2% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For 4D Molecular Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on FDMT going forward to see if this recent jump can turn into more strength down the road.
4D Molecular Therapeutics, Inc. belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Xencor (XNCR - Free Report) , closed the last trading session 0.6% lower at $28.11. Over the past month, XNCR has returned 7%.
For Xencor, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.77. This represents a change of -11.6% from what the company reported a year ago. Xencor currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in 4D Molecular Therapeutics, Inc. (FDMT): Can Its 16.0% Jump Turn into More Strength?
4D Molecular Therapeutics, Inc. (FDMT - Free Report) shares rallied 16% in the last trading session to close at $8.93. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.2% loss over the past four weeks.
The stock's surge can be attributed to the investors’ optimism around the company's third-quarter earnings, to be released soon. The optimism is being driven by the drug/biotech sector’s growth in the ongoing year.
This company is expected to post quarterly loss of $0.85 per share in its upcoming report, which represents a year-over-year change of -3.7%. Revenues are expected to be $1.7 million, up 24.2% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For 4D Molecular Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on FDMT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
4D Molecular Therapeutics, Inc. belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Xencor (XNCR - Free Report) , closed the last trading session 0.6% lower at $28.11. Over the past month, XNCR has returned 7%.
For Xencor, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.77. This represents a change of -11.6% from what the company reported a year ago. Xencor currently has a Zacks Rank of #3 (Hold).